Universal PropTech Inc. Announces Agreement with LuminUltra Technologies to Provide SARS-CoV-2 (COVID-19) Surface Testing
UPI or the
Company ) is pleased to announce that is has entered into an agreement on February 5, 2021 with LuminUltra Technologies Ltd. (
LuminUltra ) to deploy their GeneCount Rapid SARS-CoV-2 surface testing solution for UPI s current and past customers which total over 2,000 facilities including certain aviation assets in Canada today. The Agreement provides UPI the ability to provide testing services employing LuminUltra s GeneCount® qPCR tests as a service.
Chris Hazelton, President and CEO of UPI commented:
We are very excited to bring LuminUltra s
highly reputable SARS-CoV-2 surface testing solution to our customer base in Canada to ensure workplaces are sanitary and safe, Mr. Hazelton continued: